Prof. Oliver Dorigo, MD, PhD, is the Director of the
Division of Gynecologic Oncology at Stanford. He received his medical degree
from the University of Heidelberg Medical School in Germany. Following his MD
degree, he underwent residency training in Obstetrics and Gynecology at the
University of Munich, Germany. Dr. Dorigo then joined the Cancer Gene Therapy
program at the Sidney Kimmel Cancer Center in San Diego, CA, and participated
in early clinical trials using genetically modified tumor cell vaccines for the
treatment of cancer. He subsequently completed his residency in Obstetrics and
Gynecology at the UCLA David Geffen School of Medicine, Los Angeles, CA. He earned
a PhD degree in Molecular Biology for his work on the development of a new gene
transfer system that uses helper dependent adenovirus mediated delivery of an
Epstein-Barr Virus episome. Dr. Dorigo completed a clinical fellowship in
Gynecologic Oncology at UCLA/Cedars Sinai Medical Center, Los Angeles, CA. He
was a faculty member in the UCLA Division of Gynecologic Oncology from 2005 to
2013. Dr. Dorigo was then appointed as the Director of the Stanford Gynecologic
Oncology Service. At Stanford, he is directing the Clinical Research Group that
is conducting clinical trials for gynecologic cancers that mainly involve
immunotherapy.
